DE69315836D1 - Pyrazolpyridine für die behandlung der anämie - Google Patents

Pyrazolpyridine für die behandlung der anämie

Info

Publication number
DE69315836D1
DE69315836D1 DE69315836T DE69315836T DE69315836D1 DE 69315836 D1 DE69315836 D1 DE 69315836D1 DE 69315836 T DE69315836 T DE 69315836T DE 69315836 T DE69315836 T DE 69315836T DE 69315836 D1 DE69315836 D1 DE 69315836D1
Authority
DE
Germany
Prior art keywords
pct
date dec
sec
hydrogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69315836T
Other languages
English (en)
Other versions
DE69315836T2 (de
Inventor
Yutaka Kohno
Itsuo Nagatomi
Kaori Hanaoka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929212264A external-priority patent/GB9212264D0/en
Priority claimed from GB929215794A external-priority patent/GB9215794D0/en
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE69315836D1 publication Critical patent/DE69315836D1/de
Publication of DE69315836T2 publication Critical patent/DE69315836T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69315836T 1992-06-10 1993-06-07 Pyrazolpyridine für die behandlung der anämie Expired - Lifetime DE69315836T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929212264A GB9212264D0 (en) 1992-06-10 1992-06-10 New use of the pyrazolopyridine compound
GB929215794A GB9215794D0 (en) 1992-07-24 1992-07-24 New use of the pyrazolopyridine compound
PCT/JP1993/000762 WO1993025205A1 (en) 1992-06-10 1993-06-07 Pyrazolopyridine compounds for the treatment of anemia

Publications (2)

Publication Number Publication Date
DE69315836D1 true DE69315836D1 (de) 1998-01-29
DE69315836T2 DE69315836T2 (de) 1998-04-09

Family

ID=26301043

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69315836T Expired - Lifetime DE69315836T2 (de) 1992-06-10 1993-06-07 Pyrazolpyridine für die behandlung der anämie

Country Status (6)

Country Link
US (1) US5643938A (de)
EP (1) EP0644762B1 (de)
JP (1) JP3269084B2 (de)
AT (1) ATE161178T1 (de)
DE (1) DE69315836T2 (de)
WO (1) WO1993025205A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT824366E (pt) * 1995-05-10 2005-02-28 Bord Na Mona Sistema de tratamento e efluentes
US6214843B1 (en) * 1996-04-25 2001-04-10 Fujitsawa Pharmaceutical Co., Ltd. Preventives and remedies for ischemic intestinal lesion and ileus
AUPO111096A0 (en) * 1996-07-18 1996-08-08 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1998041237A1 (fr) 1997-03-18 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Medicaments pour la prevention et la therapie de l'hyperphosphatemie
DE19904396A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolbenzylamin-Derivate
DE19904406A1 (de) * 1999-02-04 2000-08-10 Bayer Ag Substituierte Pyrazolcarbonsäuren
DE19929785A1 (de) * 1999-06-29 2001-01-04 Bayer Ag Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung
US20050282751A1 (en) * 2004-03-19 2005-12-22 Ajinomoto Co., Inc. Therapeutic agent for renal anemia
WO2009016812A1 (ja) * 2007-07-27 2009-02-05 Kowa Company, Ltd. ２－フェニルキノリン－４－カルボン酸誘導体を有効成分とする貧血の予防及び／又は治療剤
EA018807B1 (ru) * 2008-10-02 2013-10-30 Эли Лилли Энд Компани Тиазолилпиразолопиримидины в качестве синтетических промежуточных соединений и связанные с ними способы синтеза
CN106986862A (zh) 2010-12-22 2017-07-28 Abbvie 公司 丙型肝炎抑制剂及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925849A (en) * 1987-06-15 1990-05-15 Fujisawa Pharmaceutical Company, Ltd. Pharmaceutically useful pyrazolopyridines
US5338743A (en) * 1988-06-06 1994-08-16 Fujisawa Pharmaceutical Co., Ltd. New use of the adenosine antagonist
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
US5459031A (en) * 1993-11-05 1995-10-17 Amgen Inc. Methods for controlling sialic acid derivatives in recombinant glycoproteins

Also Published As

Publication number Publication date
DE69315836T2 (de) 1998-04-09
EP0644762A1 (de) 1995-03-29
WO1993025205A1 (en) 1993-12-23
US5643938A (en) 1997-07-01
ATE161178T1 (de) 1998-01-15
EP0644762B1 (de) 1997-12-17
JPH08500338A (ja) 1996-01-16
JP3269084B2 (ja) 2002-03-25

Similar Documents

Publication Publication Date Title
ATE202076T1 (de) Ester der 5-aminolevulinsäure als mittel zur photosensibilisierung in der chemotherapie
FR2714378B1 (fr) Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
DE69735090D1 (de) Neurotrophin antagoniste zur behandlung von der epilepsie, alzheimer'schen krankheit und schmerzen
DE69315836D1 (de) Pyrazolpyridine für die behandlung der anämie
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
ATE169635T1 (de) Therapeutische verbindungen für die behandlung von krankheiten, die mit einem glutathion-defizit assoziiert sind, herstellungsprozess und diese enthaltene pharmazeutische zusammensetzungen
IL105122A0 (en) Benzimidazole derivative for use as an anti-irritant
PL313037A1 (en) Phenoxphenylocyclopententenylohydroxyureas
ES2104938T3 (es) Metodo de inhibir la fibrosis.
MX9201055A (es) N-[[4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracen-il] carbonil] aminoacidos utiles en la terapia de afecciones osteoarticulares.
KR950703341A (ko) 항부정맥제
BR9306870A (pt) Derivados farmacologicamente ativos de (aminometila terciária) - benzenometanol
DE59406568D1 (de) Cephalostatin-analoga und ihre verwendung als antitumormittel
EP0823254A4 (de) Neue verwendung von pyrazolopyridinverbindungen
ES2061579T3 (es) Compuestos cefem y procedimientos para su preparacion.
ES2107799T3 (es) Compuestos de cefema de actividad antimicrobiana.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP